|
Synonyms: GSK-4182136 | GSK4182136 | VIR-7831 | VIR7831 | Xevudy®
sotrovimab is an approved drug (UK & EMA (2021))
Compound class:
Antibody
Comment: Sotrovimab (VIR-7831) is a monoclonal antibody that binds to a highly conserved epitope within the surface spike glycoprotein of sarbecoviruses. The parental antibody, from which sotrovimab was derived, was originally identified in the memory B cells of a patient who had recovered from SARS-CoV infection. Sotrovimab was progressed by GSK and Vir Biotechnology as a COVID-19 therapeutic [4]. Sotrovimab retains some activity against the omicron BA.1 (B.1.1.529) SARS-CoV-2 variant (bioRxiv preprint [1]), but it activity against the BA.2 omicron subvariant is lower [3].
|
| References |
|
1. Cathcart AL, Havenar-Daughton C, Lempp FA, Ma D, Schmid MA, Agostini ML, Guarino B, Di iulio J, Rosen LE, Tucker H et al.. (2021)
The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2. biorxiv, Preprint. DOI: 10.1101/2021.03.09.434607 |
|
2. EMA.
EPAR/xevudy. Accessed on 05/01/2022. Modified on 05/01/2022. ema.europa.eu, https://www.ema.europa.eu/en/medicines/human/EPAR/xevudy |
|
3. Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, Iwatsuki-Horimoto K, Halfmann P, Watanabe S, Maeda K et al.. (2022)
Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2. N Engl J Med, 386 (15): 1475-1477. [PMID:35263535] |
|
4. Tuccori M, Ferraro S, Convertino I, Cappello E, Valdiserra G, Blandizzi C, Maggi F, Focosi D. (2020)
Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline. MAbs, 12 (1): 1854149. [PMID:33319649] |
